Healthcare Industry News: ENHANZE
News Release - November 8, 2006
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & OperationsSAN DIEGO, Nov. 8 (HSMN NewsFeed) -- Halozyme Therapeutics, Inc. (Amex: HTI ), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that William Fallon has been named Vice President, Manufacturing & Operations. Mr. Fallon will help drive all of the Company's manufacturing and operations and will report directly to Jonathan Lim, MD, Halozyme's President and CEO.
"We are thrilled to welcome Bill to our team," said Jonathan Lim. "He brings to Halozyme over 20 years of manufacturing, operations, and general management experience in the biotech industry. His addition to our team puts us in an ideal position to scale up our commercial manufacturing efforts for our FDA approved Cumulase® and Hylenex products, where we provide the active pharmaceutical ingredient, as well as to manage the supply chain for Chemophase®, ENHANZE® Technology, and other programs in development."
Mr. Fallon was previously President and Chief Executive Officer and a member of the board of directors of Cytovance Biologics, a contract manufacturing organization that provides manufacturing and development services to the biotechnology industry. At Cytovance, Mr. Fallon oversaw the design, construction, and validation of a state-of-the-art, greenfield cGMP manufacturing facility. Prior to Cytovance, from 2001 to 2003, he was Vice President of Technical Operations at Genzyme Therapeutics, having held the same position at Novazyme Pharmaceuticals, Inc. prior to its $138 million acquisition by Genzyme in 2001. He joined Novazyme and Genzyme from Transkaryotic Therapies, where he was VP of Manufacturing from 1998 to 2001. From 1993 through 1998, he was employed in several management positions for the Ares-Serono Group, culminating in the position of Vice President, US Manufacturing Operations. In this role, he served as general manager, overseeing the production and distribution of all of Serono's approved biotechnology products. Specifically, he was responsible for the production, engineering, quality assurance, quality control, human resources, finance, and materials planning/logistics departments of two commercial bulk manufacturing facilities producing mammalian cell culture derived biopharmaceutical products (Saizen® and Serostim®), employing 160 technical and administrative professionals.
From 1990 to 1992, he was Director of Manufacturing for Centocor, Inc. His prior experience also includes various management and operational roles at Invitron Corporation and Travenol-Genentech Diagnostics. Mr. Fallon earned a B.S. degree in Marine Science and a B.A. degree in Biology from Long Island University and an M.S. degree in Biology from Northeastern University.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may replace current animal slaughterhouse-derived extracts that carry potential risks of animal pathogen transmission and immunogenicity. The company has received FDA approval for two products: Cumulase®, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process; and Hylenex for use as an adjuvant to increase the absorption and dispersion of other injected drugs. The versatility of the first enzyme, rHuPH20, enables Halozyme to develop the product as a medical device, drug enhancement agent, and therapeutic drug.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the progress towards commercializing its first products and manufacturing scale up) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-KSB, 10-Q and other filings with the Securities and Exchange Commission.
Source: Halozyme Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.